• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Sebaceous gland carcinoma of the eyelid: clinicopathological features and outcome in Asian Indians.眼睑皮脂腺癌:亚洲印度人的临床病理特征及预后
Eye (Lond). 2015 Jul;29(7):958-63. doi: 10.1038/eye.2015.79. Epub 2015 May 22.
2
14-year case series of eyelid sebaceous gland carcinoma in Chinese patients and review of management.14 年中国患者眼睑皮脂腺癌病例系列及治疗回顾。
Br J Ophthalmol. 2018 Dec;102(12):1723-1727. doi: 10.1136/bjophthalmol-2017-311533. Epub 2018 Feb 19.
3
Sebaceous carcinoma of the eyelids: personal experience with 60 cases.眼睑皮脂腺癌:60例个人经验
Ophthalmology. 2004 Dec;111(12):2151-7. doi: 10.1016/j.ophtha.2004.07.031.
4
Patterns of lymphatic spread and the management of eyelid carcinomas.眼睑癌的淋巴扩散模式及治疗
Auris Nasus Larynx. 2016 Dec;43(6):666-71. doi: 10.1016/j.anl.2016.02.011. Epub 2016 Mar 7.
5
ZEB2/SIP1 as novel prognostic indicator in eyelid sebaceous gland carcinoma.ZEB2/SIP1作为眼睑皮脂腺癌的新型预后指标
Hum Pathol. 2015 Oct;46(10):1437-42. doi: 10.1016/j.humpath.2015.05.026. Epub 2015 Jun 10.
6
Impact of clinicopathologic factors on survival in patients with sebaceous carcinoma of the eyelid - a population-based analysis.临床病理因素对眼睑皮脂腺癌患者生存的影响——一项基于人群的分析。
Orbit. 2019 Aug;38(4):261-268. doi: 10.1080/01676830.2018.1505922. Epub 2018 Oct 29.
7
Prognosis of eyelid sebaceous gland carcinoma based on the tumor (T) category of the American Joint Committee on Cancer (AJCC) classification.基于美国癌症联合委员会(AJCC)分类的肿瘤(T)类别对眼睑皮脂腺癌的预后评估
Int Ophthalmol. 2016 Oct;36(5):681-90. doi: 10.1007/s10792-016-0187-6. Epub 2016 Feb 1.
8
Eyelid sebaceous gland carcinoma, validation of AJCC 8th edition T staging- a retrospective study from North India.眼睑皮脂腺癌 AJCC 第 8 版 T 分期的验证-来自印度北部的回顾性研究。
Acta Ophthalmol. 2023 Feb;101(1):49-56. doi: 10.1111/aos.15204. Epub 2022 Jun 24.
9
Neoadjuvant Systemic Chemotherapy in the Management of Extensive Eyelid Sebaceous Gland Carcinoma: A study of 10 Cases.新辅助全身化疗在广泛型眼睑皮脂腺癌治疗中的应用:一项10例病例的研究
Ophthalmic Plast Reconstr Surg. 2016 Jan-Feb;32(1):35-9. doi: 10.1097/IOP.0000000000000398.
10
Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid.眼睑转移性皮脂腺癌的治疗与转归
Int J Dermatol. 2008 Mar;47(3):276-9. doi: 10.1111/j.1365-4632.2008.03496.x.

引用本文的文献

1
AI assistance enhances histopathologic distinction between sebaceous and squamous cell carcinoma of the eyelid.人工智能辅助提高了眼睑皮脂腺癌和鳞状细胞癌之间的组织病理学鉴别能力。
NPJ Digit Med. 2025 Jul 4;8(1):406. doi: 10.1038/s41746-025-01775-z.
2
Clinical presentation and prognostic factors of eyelid sebaceous carcinoma.眼睑皮脂腺癌的临床表现及预后因素
Jpn J Ophthalmol. 2025 May 25. doi: 10.1007/s10384-025-01187-2.
3
Multimodal treatment with Neoadjuvant chemotherapy for eyelid and periocular sebaceous gland carcinoma: Long-term outcomes.眼睑及眼周皮脂腺癌新辅助化疗的多模式治疗:长期疗效
Am J Ophthalmol Case Rep. 2025 Feb 5;38:102272. doi: 10.1016/j.ajoc.2025.102272. eCollection 2025 Jun.
4
Molecular landscape of eyelid sebaceous gland carcinoma: A comprehensive review.眼睑皮脂腺癌的分子特征:全面综述。
Indian J Ophthalmol. 2024 Oct 1;72(10):1393-1403. doi: 10.4103/IJO.IJO_167_24. Epub 2024 Sep 27.
5
Clinicopathologic Features of Eyelid Sebaceous Gland Carcinoma Requiring Immunohistochemical Diagnosis.需要免疫组化诊断的眼睑皮脂腺癌的临床病理特征
Ocul Oncol Pathol. 2024 Sep;10(3):131-138. doi: 10.1159/000538537. Epub 2024 Apr 29.
6
Periocular Sebaceous Carcinoma: A Case Audit from the National Specialist Ophthalmic Pathology Service in Liverpool from 2009 to 2022 to Assess the Diagnostic Utility of PRAME Expression.眼周皮脂腺癌:来自利物浦国家专业眼科病理服务中心2009年至2022年的病例审核,以评估PRAME表达的诊断效用。
Ocul Oncol Pathol. 2024 Apr;10(1):1-8. doi: 10.1159/000535169. Epub 2023 Dec 10.
7
Establishment and Characterization of a TP53-Mutated Eyelid Sebaceous Carcinoma Cell Line.建立并鉴定一个携带 TP53 基因突变的眼睑皮脂腺癌细胞系。
Invest Ophthalmol Vis Sci. 2023 Dec 1;64(15):16. doi: 10.1167/iovs.64.15.16.
8
Sebaceous Neoplasms.皮脂腺肿瘤
Diagnostics (Basel). 2023 May 9;13(10):1676. doi: 10.3390/diagnostics13101676.
9
Prognostic risk factors and nomogram construction for sebaceous carcinoma: A population-based analysis.皮脂腺癌的预后危险因素及列线图构建:一项基于人群的分析。
Front Oncol. 2023 Feb 27;13:981111. doi: 10.3389/fonc.2023.981111. eCollection 2023.
10
Clinicopathological Study of Meibomian Carcinoma of Eyelids - An Experience of Two Years in a Tertiary Care Center.眼睑的睑板腺癌的临床病理研究-在一家三级护理中心的两年经验。
Middle East Afr J Ophthalmol. 2022 Nov 23;29(1):15-18. doi: 10.4103/meajo.meajo_298_21. eCollection 2022 Jan-Mar.

本文引用的文献

1
Neoadjuvant Systemic Chemotherapy in the Management of Extensive Eyelid Sebaceous Gland Carcinoma: A study of 10 Cases.新辅助全身化疗在广泛型眼睑皮脂腺癌治疗中的应用:一项10例病例的研究
Ophthalmic Plast Reconstr Surg. 2016 Jan-Feb;32(1):35-9. doi: 10.1097/IOP.0000000000000398.
2
Diagnostic utility of adipophilin immunostain in periocular carcinomas.眼周癌中脂联素免疫染色的诊断效用。
Ophthalmology. 2014 Apr;121(4):964-71. doi: 10.1016/j.ophtha.2013.10.041. Epub 2013 Nov 28.
3
Eyelid sebaceous carcinoma: clinicopathologic and multiparametric immunohistochemical analysis that includes adipophilin.眼睑皮脂腺癌:临床病理和多参数免疫组织化学分析,包括脂肪分化相关蛋白。
Am J Ophthalmol. 2014 Jan;157(1):186-208.e2. doi: 10.1016/j.ajo.2013.08.015. Epub 2013 Oct 7.
4
Observational prospective cohort study of patients with newly-diagnosed ocular sebaceous carcinoma.初诊眼部皮脂腺癌患者的观察性前瞻性队列研究。
Br J Ophthalmol. 2013 Jan;97(1):47-51. doi: 10.1136/bjophthalmol-2012-302443. Epub 2012 Oct 31.
5
A retrospective review of 1349 cases of sebaceous carcinoma.对1349例皮脂腺癌病例的回顾性研究。
Cancer. 2009 Jan 1;115(1):158-65. doi: 10.1002/cncr.23952.
6
Sebaceous cell carcinoma of the ocular adnexa: clinical presentations, histopathology, and outcomes.眼附属器皮脂腺癌:临床表现、组织病理学及预后
Ophthalmic Plast Reconstr Surg. 2008 May-Jun;24(3):194-200. doi: 10.1097/IOP.0b013e31816d925f.
7
Sebaceous carcinoma of the caruncle.睑裂部皮脂腺癌
Cornea. 2006 Aug;25(7):858-9. doi: 10.1097/01.ico.0000224641.35977.e4.
8
Sebaceous carcinoma of the ocular region: a review.眼部皮脂腺癌:综述
Surv Ophthalmol. 2005 Mar-Apr;50(2):103-22. doi: 10.1016/j.survophthal.2004.12.008.
9
Sebaceous carcinoma of the eyelids: personal experience with 60 cases.眼睑皮脂腺癌:60例个人经验
Ophthalmology. 2004 Dec;111(12):2151-7. doi: 10.1016/j.ophtha.2004.07.031.
10
Improved survival rates in sebaceous carcinoma of the eyelid.眼睑皮脂腺癌生存率的提高。
Eye (Lond). 2004 Jan;18(1):49-53. doi: 10.1038/sj.eye.6700523.

眼睑皮脂腺癌:亚洲印度人的临床病理特征及预后

Sebaceous gland carcinoma of the eyelid: clinicopathological features and outcome in Asian Indians.

作者信息

Kaliki S, Ayyar A, Dave T V, Ali M J, Mishra D K, Naik M N

机构信息

Institute for Eye Cancer, Hyderabad, India.

Ophthalmic Pathology Service, L V Prasad Eye Institute, Hyderabad, India.

出版信息

Eye (Lond). 2015 Jul;29(7):958-63. doi: 10.1038/eye.2015.79. Epub 2015 May 22.

DOI:10.1038/eye.2015.79
PMID:25998946
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4506352/
Abstract

PURPOSE

To study the clinical and histopathological features of eyelid sebaceous gland carcinoma (SGC) and to evaluate the prognosis in the Asian-Indian population.

METHODS

This is a retrospective study of 191 patients with SGC.

RESULTS

The mean age at presentation of eyelid SGC was 57 years (median, 56 years). The tumor epicenter was most commonly located in the upper eyelid (n=125, 65%). The mean tumor basal diameter was 15 mm (median, 10 mm). There was evidence of tumor extension into the orbit (n=30, 16%), paranasal sinuses (n=3, 2%), and brain (n=1, 1%). Wide excision biopsy (n=146, 78%) was the most common treatment modality. Tumor recurrence was noted in 42 (24%) patients over a mean follow-up period of 29 months (median, 20 months). On the basis of the Kaplan-Meier estimate, lymph node metastasis occurred in 18%, systemic metastasis was detected in 10%, and death occurred in 2% of patients at 10 years. On multivariate analysis, the factors predicting locoregional lymph node and systemic metastasis were medial canthal involvement (P=0.004; P=0.013), lateral canthal involvement (P=0.013; P=0.025), tumor basal diameter >10 mm (P=0.002; P=0.002), and perivascular invasion (P=0.043; P<0.001), respectively. The factors predicting death due to metastasis on multivariate analysis were medial canthal involvement (P=0.012) and tumor basal diameter >10 mm (P=0.001).

CONCLUSION

Advanced eyelid SGC is a tumor associated with poor prognosis. In this study, canthal involvement, larger tumor diameter, and perivascular invasion were poor prognostic factors.

摘要

目的

研究眼睑皮脂腺癌(SGC)的临床和组织病理学特征,并评估亚洲印度人群的预后。

方法

这是一项对191例SGC患者的回顾性研究。

结果

眼睑SGC患者就诊时的平均年龄为57岁(中位数为56岁)。肿瘤中心最常见于上睑(n = 125,65%)。肿瘤基底平均直径为15毫米(中位数为10毫米)。有证据表明肿瘤侵犯眼眶(n = 30,16%)、鼻窦(n = 3,2%)和脑(n = 1,1%)。广泛切除活检(n = 146,78%)是最常见的治疗方式。在平均29个月(中位数为20个月)的随访期内,42例(24%)患者出现肿瘤复发。根据Kaplan-Meier估计,10年时18%的患者发生淋巴结转移,10%的患者检测到远处转移,2%的患者死亡。多因素分析显示,预测局部区域淋巴结和远处转移的因素分别为内眦受累(P = 0.004;P = 0.013)、外眦受累(P = 0.013;P = 0.025)、肿瘤基底直径>10毫米(P = 0.002;P = 0.002)和血管周围侵犯(P = 0.043;P<0.001)。多因素分析预测因转移导致死亡的因素为内眦受累(P = 0.012)和肿瘤基底直径>10毫米(P = 0.001)。

结论

晚期眼睑SGC是一种预后不良的肿瘤。在本研究中,眦部受累、较大的肿瘤直径和血管周围侵犯是不良预后因素。